PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.
Hospital-Grade Hygiene Meets 30% Faster Heating for Parents on the Move
CHICAGO, July 4, 2025 /PRNewswire/ -- Papablic, a pioneer in baby care innovation, launched the...
INRS team is exploring the potential of saponins, a group of natural molecules found in many plants
LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic...
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...
AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President...
AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President...